Événements
2018 BIO International Convention
4-7 June, 2018
Boston, USA
“The BIO International Convention is hosted by the Biotechnology Innovation Organization, which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products”.
Meet2Win 2018 – Oncology Business Convention
17-18 May, 2018
Bordeaux, France
“MATWIN organises in Bordeaux on May 17th and 18th 2018 the 4th edition of its European Business Convention entirely dedicated to open innovation, collaborative research and technology transfer: MEET2WIN.
Organized around one-to-one meetings and bringing together all the parties involved in oncology innovation, MEET2WIN offers the opportunity to meet representatives of big pharma companies, biotechs, start-up, project leaders researchers, clinicians, TTO’s, investors etc. to increase R&D private/public partnerships”.
Genesis Drug Discovery 2018
10 – 11 May, 2018
Barcelona, Spain
“Genesis Drug Discovery (GDD) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange that will give all the participants the opportunity to share their experiences, foster collaborations across industry and academia and evaluate emerging technologies across the globe.
Genesis Drug Discovery (GDD) provides a platform to promote international exchanges for drug discovery, and to accelerate the cooperation for new drug research and development in the global market.
Congrès International sur les maladies du foie 2018 de l’EASL
Avril 11-15, 2018
ENYO Pharma est fier d’annoncer que son poster a été sélectionné pour être présenté lors du Congrès International sur les maladies du foie de l’EASL se déroulant à Paris du 11 au 15 Avril. L’équipe d’ENYO Pharma présentera ses dernières études ainsi que les résultats sur l’Hépatite B de son composé EYP001 (agoniste FXR) développé pour les patients atteints d’hépatite B chronique. Le Congrès annuel, qui a pour objectif de présenter les derniers sujets de recherche sur les maladies du foie,
J.P. Morgan 36th Annual Healthcare Conference
January 8-11, 2018
San Francisco, CA, California
“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, hosting the largest and most informative healthcare investment symposium in the industry. In 2018, more than 400 companies are expected, both public and private, to deliver presentations to more than 8,000 attendees.” (jpmorgan.com)
Dernière press release 